Table 6. Cost-effectiveness^a of various cardiovascular (CV) risk management strategies in people aged 40–64 years, Seychelles, 2004.

Management strategy	People to treatb	CV events avertedb	NNTc	Medication cost
				Seychelles (2004 US$)			India (2005 US$)
				Annually (millions)	Per CV event averted		Annually (millions)	Per CV event averted
Single-risk-factor
BP ≥ 140/90 mmHg	44 899	127	354	3.25	25 679		1.84	14 534
TSC ≥ 6.2 mmol/l	28 317	39	727	15.09	387 275		1.24	31 831
BP ≥ 140/90 mmHg or TSC ≥ 6.2 mmol/l	59 741	157	379	25.27	160 452		3.89	24 678
Total CV risk
CV risk ≥ 10%	10 837	137	79	NAd	NA		1.03	7 499
CV risk ≥ 20%	5 114	92	56	NA	NA		0.49	5 291
CV risk ≥ 20% or BP ≥ 160/100 mmHg or TSC ≥ 8.0 mmol/l	20 653	147	140	NA	NA		1.96	13 307
Current situation	37 667	103	366	15.93	154 674		2.45	23 789

BP, blood pressure; NNT, number needed to treat; TSC, total serum cholesterol; US$, United States dollars.

^a All cost and cost-effectiveness estimates are based on the prices of medications only and on the assumptions that all persons in the population who have a specified condition are known and that adherence to treatment is 100%.

^b Annually per 100 000 people aged 40–64 years. For “people to treat” the figures correspond to the prevalences of the specified conditions per 100 000 people.

^c Number of persons aged 40–64 years that one would need to treat annually (per 100 000) to avoid one fatal or non-fatal CV event.

^d Not applicable since the polypill is not yet available in Seychelles.